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Introduction 
 
Diabetes mellitus (DM) is a chronic endocrine disease characterized by higher-than-optimal 
blood sugar levels. It has two major forms, namely type 1 and type 2 diabetes (T1DM; 
T2DM) that are different in their basic pathophysiological features. T1DM develops due to 
the autoimmune destruction of the pancreatic β-cells, which leads to insulinopenia. In 
contrast, hyperinsulinemia and insulin resistance are the major drives in T2DM. Regardless of 
its mechanism, the altered metabolism in DM leads to the manifestation of a special cardiac 
disease, called diabetic cardiomyopathy. Therefore, the diabetes “epidemic” contributes not 
only to the increased cardiovascular mortality but also raises the economic burden of cardiac 
diseases. Consequently, novel therapies are urgently needed in order to treat and prevent 
diabetes-associated disorders. 
The development of diabetic cardiomyopathy is associated with characteristic changes of the 
cardiac structure and function. Several key morphological and molecular features have been 
described in the pathophysiology of the disease. The dysfunctional metabolism in DM 
(disturbances in insulin signaling, diminished activity and downregulation of the glucose 
transporter type 4, substrate switching in the heart including reduced glucose and lactate and 
increased free fatty acid supply) results in increased nitrosative and oxidative stress in the 
cardiac tissue. Moreover, lipid overload, hyperglycemia-induced glucotoxicity, inflammation 
and overactivation of reactive oxygen species (ROS)-producing enzymes (e.g. nicotinamide 
adenine dinucleotide phosphate-oxidases) and mitochondrial dysfunction together contribute 
to the production of oxidative agents such as superoxide. Superoxide thereafter reacts with 
different molecules including nitric oxide (NO) to form the highly reactive nitrosative agent 
peroxynitrite. Peroxynitrite is able to bind and damage different structural elements in the 
cardiac tissue including enzymes, DNA and the members of the contractile apparatus. These 
processes together cause significant cardiac dysfunction in DM (mainly systolic dysfunction 
in T1DM and mainly diastolic dysfunction in T2DM). 
The NO – cyclic guanosine monophosphate (cGMP) – soluble guanylate cyclase (sGC) – 
protein kinase G (PKG) signaling pathway has been described to exert anti-hypertrophic, anti-
fibrotic and anti-apoptotic effects in various cardiovascular disorders. The activity of the 
pathway depends on the intracellular level of the second messenger cGMP, which is regulated 
by two main ways: 1) sGC is responsible for its production while 2) phosphodiesterase-5A 
(PDE5A) (dominantly in the heart) is responsible for the degradation of the molecule.  
DM, however, through the presence of oxidative stress leads to the deterioration of the above 
signalling pathway. Main points of the dysregulation of cGMP signaling are the oxidative 
3 
 
deactivation of sGC and the overactivation of the PDE5A enzyme. Theese processes together 
significantly decrease the intracellular amount of cGMP thereby deactivation of PKG 
pathway occurs.  
Novel pharmacological modulators of the NO-cGMP-sGC-PKG signaling have been 
developed in recent years. A promising novel class of drugs, the sGC activators are able to 
reactivate the dysfunctional enzyme by binding to its heme-binding subunit in oxidative 
stress. Cinaciguat, a member of the sGC activators, has been described to have beneficial 
effects in experimental myocardial infarction, myocardial ischemia/reperfusion injury, 
endothelial dysfunction induced by nitro-oxidative stress and in the prevention of cardiac 
hypertrophy. Cinaciguat has demonstrated efficacy in a proof-of-concept study in patients 
with acute decompensated heart failure, however, the acute intravenous use of the drug for the 
same indication in a phase-IIb clinical study was associated with high number of hypotension 
as adverse event. Therefore, the study has been prematurely terminated but the investigators 
concluded that rather a chronic oral application could have beneficial effects in chronic heart 
failure patients.  
Another point of intervention in cGMP signaling is PDE5A inhibition. PDE5A inhibitors 
(such as vardenafil) are on-demand treatment for erectile dysfunction. The crucial role of 
PDE5A in myocardial remodeling has been described in PDE5A knockout mice. The 
protective effects of enhanced cGMP-signaling via pharmacological inhibition of PDE5A by 
vardenafil have been demonstrated in several cardiovascular diseases, such as acute 
myocardial infarction, cardiac hypertrophy, heart failure and drug-induced cardiotoxicity. The 
beneficial effects on heart failure patients of the PDE5A inhibitor sildenafil have been 
investigated in a clinical trial. However, sildenafil failed to improve exercise capacity and the 
clinical outcomes in advanced heart failure patients. In spite of that, PDE5A inhibition has 
been proposed to be of therapeutic importance in heart failure patients with DM. 
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Objectives 
 
Recent literature data have drawn the attention to the importance of co-morbidities in heart 
failure patients as they significantly affect the mortality and morbidity. Among the different 
co-morbidities, DM is a major one. Although DM accounts for a large portion of mortality of 
heart failure patients as a contributor to different cardiovascular diseases, DM itself leads to 
the development of heart failure regardless of the effect on coronary artery disease or 
hypertension.  
To date, the pharmacological therapy of multi-morbid heart failure patients is far from 
optimal. Therefore, co-morbidities have to be taken into account as part of personalized 
medicine and for that novel drugs are needed to treat patients appropriately. Enhancement of 
cGMP signaling in the myocardium might provide a novel and promising therapeutic option 
to treat diabetic heart failure. 
Based on that, the aims of our present investigations were as follows: 
 
1. Comparison of the functional (systolic and diastolic) and the structural hallmarks 
(oxidative stress, fibrotic and hypertrophic remodeling and apoptosis) of diabetic 
cardiomyopathy in animal models of T1DM and T2DM  
 
2. Revelation of the alterations of NO-cGMP signaling in diabetic cardiomyopathy in the 
two types of DM 
 
3. Explore the possible therapeutic effects of sGC activation by the novel sGC activator 
cinaciguat in T1DM-associated diabetic cardiomyopathy 
 
4. Study the potential cardioprotective effects of the PDE5A inhibitor vardenafil on the 
development of T2DM-related diabetic cardiomyopathy 
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Methods 
 
Model of T1DM 
T1DM was induced in young male Sprague-Dawley (SD) rats with a single i.p. injection of 
streptozotocin (60 mg/kg). 72h after induction animals with a random blood glucose level >15 
mmol/l were considered to be diabetic and were included into the study. Experiments were 
performed after 8 weeks of DM duration. 
 
Model of T2DM 
Zucker Diabetic Fatty (ZDF) rat was used as a model of T2DM. Homozygous recessive males 
(fa/fa) develop obesity, fasting hyperglycemia and DM due to a genetic mutation of the leptin 
receptor and a special diet (Purina #5008). Homozygous dominant (+/+) and heterozygous 
(fa/+) lean genotypes remain healthy. Seven-week old male ZDF diabetic (fa/fa) and ZDF 
lean (+/?) rats were used. Experiments were performed at the age of 32 weeks. 
 
Study protocol 
For comparative investigation 16-week-old SD and 32-week-old ZDF rats were used. 
Cinaciguat was tested in T1DM. Groups: vehicle-treated control (Co; n=12), cinaciguat-
treated control (CoCin; n=12), vehicle-treated diabetic (DiabCo; n=12) and cinaciguat-treated 
diabetic (DiabCin; n=10) groups. Eight-week old animals were treated vehicle (Co, DiabCo) 
or with cinaciguat per os (CoCin, DiabCin; 10 mg/kg/day) for eight weeks. 
Vardenafil was tested in ZDF rats. Seven-week old male ZDF diabetic (fa/fa) and ZDF lean 
(+/?) rats were divided into four groups: vehicle-treated controls (ZDFLean; n=8), vardenafil-
treated controls (ZDFLean+Vard; n=7), vehicle-treated diabetic (ZDF; n=7) and vardenafil-
treated diabetic (ZDF+Vard; n=8). Rats were treated with 10 mg/kg vardenafil continuously 
or with vehicle (0.01 mol/l citrate buffer) orally for 25 weeks. 
 
Biochemistry 
Blood glucose and urine glucose was determined. Plasma cGMP and plasma nitrite/nitrate 
levels were measured. 
 
Echocardiography 
The cardiac morphology of ZDF was studied by echocardiography under 1-2% isoflurane 
anesthesia. B-mode images were acquired in the long-axis and in the short-axis at the mid-
papillary level and left ventricular (LV) anterior, posterior wall thicknesses (LVAW; LVPW) 
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and LV internal diameter (LVID) were measured in end-systole and end-diastole (‘s’ and ‘d’). 
The following parameters were calculated: LVmass=1.04x[(LVAWd+LVIDd+LVPWd)3-
LVIDd3], relative wall thickness (RWT)=(LVAWd+LVPWd)/LVIDd. LVmass was 
normalized to the body weight (BW; kg) (LVmass index) and to the tibia length 
(LVmass/TL). 
 
In vivo hemodynamic investigation 
Invasive hemodynamic investigation was performed in order to characterize cardiac function 
in detail and to assess the effect of drug treatments. The following parameters were measured 
by LV pressure-volume analysis (P-V): mean arterial pressure (MAP), heart rate (HR), LV 
systolic pressure (LVSP), LV end-diastolic pressure (LVEDP), maximal slope of systolic 
pressure increment (dP/dtmax) and diastolic pressure decrement (dP/dtmin), time constant of LV 
pressure decay (TauW; Weiss method), ejection fraction (EF), stroke work (SW) and cardiac 
output (CO), the slope of LV end-systolic P-V relationship (Ees; curvilinear model), preload 
recruitable stroke work (PRSW) and the slope of LV end-diastolic P-V relationship 
(EDPVR). 
 
Force measurement in permeabilized left ventricular cardiomyocytes 
Permeabilized rat LV cardiomyocytes were mounted in a mechanical apparatus to measure 
isometric force and sarcomere length (SL). Maximal active force (Fmax; in the presence of a 
saturating Ca2+ concentration) and Ca2+-independent passive force (Fpassive; in relaxing 
solution) were measured at a SL 2.3 µm, while Fpassive was also registered for a range of SLs 
(between 1.9 µm and 2.5 µm). 
 
Gene expression studies 
From LV mRNA samples, the expression of the following genes were measured by 
quantitative reverse transcription polymerase chain reactions: catalase, glutathione reductase 
(GSR), superoxide dismutase 1 and 2 (SOD1 and 2), thioredoxin-1, atrial natriuretic factor 
(ANF), myosin heavy chain alpha and beta (α- and β-MHC), Bcl-2, Bcl2-associated X protein 
(BAX), endothelial NO synthase (eNOS), heat shock protein 70a1 (HSP70a1), matrix 
metallopeptidase 2 and 9 (MMP-2 and 9), tissue inhibitor of MMP 1 and 2 (TIMP-1 and 2), 
collagen 1a1 and 3a1 (Col1a1 and 3a1), fibronectin, phospholamban (PLB), caspase-12, c-fos, 
c-jun and endothelin-1 (ET-1). Gene expression data were normalized to glyceraldehyde-3-
phosphate dehydrogenase (GAPDH). 
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Western blotting 
Protein expression of eNOS, sGC, PDE5A, PKG, vasodilator stimulated phosphoprotein 
(VASP) and phosphorilated-VASP (p-VASP), MMP-2 and 9, transforming growth factor β1 
(TGF-β1), PLB, p-PLB, poly (ADP-ribose) polymerase (PARP1) were investigated by 
western blot. GAPDH and tubulin were used as loading controls. 
 
Histopathology and immunohistochemistry 
We performed hematoxylin and eosin (HE), Masson’s trichrome (MT) and Picrosirius red 
staining to assess cardiomyocyte hypertrophy (cardiomyocyte diameter) and fibrosis (MT 
score and pircosirius red area). Additionally, 3-nitrotyrosine (3-NT, marker of nitro-oxidative 
stress), cGMP, TGF-β1 and fibronectin immunohistochemistries were done. Terminal 
deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) assay was performed to 
assess DNA fragmentation and apoptosis. 
 
Statistical analysis 
Data are presented as means and standard errors of the mean (SEM). Shapiro-Wilk’s 
normality test was used. A p <0.05 was used as a criterion of significance.  
 
Comparative investigation of T1DM and T2DM-related diabetic cardiomyopathy 
An unpaired two-sided Student’s t-test was used. To compare diabetes-induced alterations 
between the two models individual data of each animal was normalized to the average value 
of the corresponding control group. 
 
Experiments on the effect of sGC activation in T1DM-related diabetic cardiomyopathy 
Two-way analysis of variance (ANOVA) with “T1DM” and “Cinaciguat” as independent 
factors was carried out. Tukey HSD post hoc test was used to assess intergroup differences.  
 
Experiments on the effect of PDE5A inhibition in T2DM-related diabetic cardiomyopathy 
Two-way ANOVA with “T2DM” and “Vardenafil” as independent factors was carried out. 
Tukey HSD post hoc test was used to assess intergroup differences. 
 
Drugs 
Cinaciguat was suspended in 0.5% methylcellulose solution. Vardenafil was dissolved in 0.01 
mol/l citrate buffer. 
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Results 
 
Comparative investigation of diabetic cardiomyopathy in T1DM and T2DM 
 
Basic characteristics 
DM was associated with decreased BW and increased blood and urine glucose levels.  
 
Nitro-oxidative stress 
DM was characterized by increased nitro-oxidative stress, as indicated by the higher 3-NT 
immunoreactivity and upregulation of different antioxidant systems (catalase, thioredoxin-1, 
GSR, HSP70a1, SOD1 and SOD2) in the LV. Interestingly, the extent of nitro-oxidative 
stress was more pronounced in T1DM compared to T2DM. 
 
Cardiac hypertrophy and fibrosis 
Cardiac remodeling was a common hallmark of both DM models. We observed significantly 
increased HW/BW ratio in DM. Echocardiography findings supported cardiac hypertrophy in 
ZDF rats. Accordingly, cardiomyocyte diameter was increased in both types of DM indicating 
the presence of cardiomyocyte hypertrophy. An altered pattern of myocardial gene expression 
was observed including increased ANF, β/α-MHC, ET-1, c-fos and c-jun expressions. 
Additionally, the altered metabolism in DM led to the development of myocardial fibrosis in 
the heart of the animals (as shown by increased MT score and Picrosirius areas and 
upregulated TGF-β and fibronectin expression, and by the dysregulation of MMPs and 
Col1a1 and 3a1 production). Similar to nitro-oxidative stress, the pathological remodeling of 
the heart was more pronounced in type 1 diabetic animals when compared to ZDF rats. 
 
DNA injury and apoptosis 
The extensive nitro-oxidative stress resulted in DNA injury and apoptosis as indicated by the 
elevated number of TUNEL positive cardiomyocyte nuclei in the myocardium. We observed 
that the more pronounced oxidative stress in T1DM was associated with more prominent 
increase of DNA injury and apoptosis. We found that caspase-3 and PARP1 activation were 
elevated, while BAX/Bcl-2 ratio was unchanged. 
 
Alterations of the NO-sGC-cGMP-PKG signaling 
Significant deterioration of the NO-sGC-cGMP-PKG signaling pathway was found as 
myocardial cGMP levels were significantly lower and PDE5A was upregulated in the diabetic 
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myocardium regardless of its type. The downregulation of eNOS might have further 
contributed to this phenomenon in T1DM. Consequently, the activity of this pathway was 
diminished in both types of DM as shown by the lower p-VASP/VASP ratios. Interestingly, 
plasma total nitrite/nitrate levels were not different in type 2 diabetic animals. 
 
In vivo and in vitro cardiac function 
 MAP was not different between diabetic and corresponding controls while HR was lower in 
T1DM when compared with its control group. Classical systolic parameters (EF, CO, 
dP/dtmax, LVSP, SW) and the sensitive contractility indices (Ees, PRSW) showed significant 
decrease  in  T1DM  (Figure  1A).  Despite  these  alterations T2DM  was  characterized  by 
 
Figure 1. Cardiac dysfunction in T1DM and T2DM models 
Contractility indices (A): slope of end-systolic pressure-volume relationship (Ees), ejection 
fraction (EF). Stiffness parameters (B): slope of end-diastolic pressure-volume relationship 
(EDPVR), slope of end-diastolic pressure (LVEDP). Groups: SD control, streptozotocin 
(STZ)-induced diabetic SD, Zucker Diabetic Fatty (ZDF) lean, and ZDF. Percent changes 
between diabetic and corresponding non-diabetic control groups are indicated in both DM 
models. *p<0.05 vs. the corresponding non-diabetic group. 
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preserved systolic function (unchanged systolic and contractile indices) (Figure 1A). Cardiac 
relaxation (TauW) was markedly impaired in both animal models. Significant increase of 
EDPVR and LVEDP was observed only in T2DM demonstrating pronounced LV diastolic 
stiffness (Figure 1B). In vitro force measurement of LV cardiomyocytes showed elevated 
Fpassive without the change of Fmax as an indicative of cardiomyocyte stiffness at the sarcomere 
level. 
 
 
Effects of cinaciguat on T1DM-associated cardiomyopathy 
 
Basic characteristics 
Cinaciguat had no effect on blood glucose levels and on HW, BW and HW/BW ratio. 
 
Nitro-oxidative stress 
Cinaciguat effectively reduced the DM-associated increase of 3-NT immunoreactivity and 
prevented the upregulation of the different antioxidant enzymes. 
 
Cardiac hypertrophy and fibrosis 
Cinaciguat had anti-fibrotic effects in T1DM, as it decreased the TGF-β1 immunoreactivity 
and the MT positive area of the myocardium. Cinaciguat prevented MMP dysregulation by 
reverting MMP/TIMP ratios to control levels. Anti-hypertrophic effects of the drug were 
confirmed by lower cardiomyocyte diameter and reduced ANF gene expression in T1DM. 
 
DNA injury and apoptosis 
Cinaciguat reduced DNA injury and apoptosis (less number of TUNEL positive nuclei) in 
DM when compared to DiabCo animals. It had no effect on BAX/Bcl2 ratio. 
 
Alterations of the NO-sGC-cGMP-PKG signaling 
Cinaciguat restored the activity of the NO-sGC-cGMP-PKG signaling [elevated 
plasma/cardiac cGMP levels, lower PDE5A protein expression and increased ratio of p-
VASP/VASP (marker of PKG activity)] in T1DM.  
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In vivo cardiac function 
Cinaciguat improved cardiac performance in T1DM (Figure 2.). Sytolic function was 
preserved as represented by improved PRSW and EF, while diastolic active relaxation and LV 
diastolic stiffness were also improved (shortened TauW and lower LVEDP and EDPVR). 
 
Figure 2. Effect of cinaciguat on cardiac performance in T1DM 
(A) Representative pressure-volume (P-V) loops, (B) preload recruitable stroke work 
(PRSW), slope of LV end-systolic P-V relationship (Ees) and the slope of LV end-diastolic P-
V relationship (EDPVR) are presented in vehicle-treated control (Co), cinaciguat-treated 
control (CoCin), vehicle-treated diabetic (DiabCo) and cinaciguat-treated diabetic (DiabCin) 
groups. *p<0.05 vs. Co, #p<0.05 vs. DiabCo 
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Effects of vardenafil on T2DM-associated cardiomyopathy 
 
Basic characteristics 
The PDE5A inhibitor vardenafil had no effect on BW, HW, HW/BW and on glucose levels.  
 
Nitro-oxidative stress 
Vardenafil treatment successfully prevented the T2DM-associated increase of nitro-oxidative 
stress (indicated by lower LV 3-NT content, lower gene expression of catalase and 
thioredoxin-1) in the LV of ZDF rats. 
 
Cardiac hypertrophy and fibrosis 
Application of vardenafil had anti-hypertrophic and anti-fibrotic effects on diabetic 
cardiomyopathy in ZDF rats. Namely, echocardiography markers of myocardial hypertrophy 
LVAWs and LVAWd were significantly lower in vardenafil-treated ZDF rats, while ANF 
gene expression and cardiomyocyte diameter/TL were also reduced in ZDF+Vard animals 
when compared to ZDF rats. Furthermore, vardenafil showed anti-fibrotic properties as it 
decreased both MT score and Picrosirius positive area and fibronectin gene expression value 
in ZDF rats.  
 
DNA injury and apoptosis 
The T2DM-induced elevation of TUNEL positive cardiomyocyte nuclei, cleaved caspase-3 
and cleaved PARP1 levels in the LV of ZDF rats were successfully prevented by chronic 
application of vardenafil.  
 
Alterations of the NO-sGC-cGMP-PKG signaling 
Although vardenafil had no effect on plasma total nitrite/nitrate levels, it effectively restored 
the activation of the NO-sGC-cGMP-PKG signaling pathway by increasing plasma/cardiac 
cGMP levels, by lowering the protein amount of PDE5A and restoring the activity of PKG 
(restored p-VASP/VASP ratio). In spite of that, p-PLB/PLB ratio was not altered among the 
groups. 
 
In vivo and in vitro cardiac function 
T2DM was associated with diastolic dysfunction characterized by increased myocardial 
stiffness (steeper slope of EDPVR) (Figure 3A, B) and prolonged TauW. In contrast, systolic 
function was preserved (Figure 3A, C). Accordingly, in vitro cardiomyocyte function was 
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characterized by increased cardiomyocyte stiffness (elevated Fpassive) while Fmax did not 
change. Diabetic cardiomyopathy-associated severe diastolic dysfunction was effectively 
prevented  by  the  application of vardenafil as the slope of  EDPVR significantly improved in 
 
Figure 3. Effects of vardenafil on in vivo and in vitro myocardial function in T2DM 
(A) Representative left ventricular (LV) pressure-volume (P-V) loops. (B) Slope of end-
diastolic P-V relationship (EDPVR). (C) Slope (Ees) of the LV end-systolic P-V relationships. 
The arrow indicates the increase of EDPVR (a marker of cardiac stiffness) in ZDF. Groups: 
vehicle-treated controls (ZDFLean), vardenafil-treated controls (ZDFLean+Vard), vehicle-
treated diabetic (ZDF) and vardenafil-treated diabetic (ZDF+Vard). *p< 0.05 vs. ZDFLean; 
#p< 0.05 vs. ZDF 
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ZDF rats (Figure 3A, B). Moreover, Fpassive, a marker of cardiomyocyte stiffness, improved at 
different sarcomere lengths. It is notable, that the slope of EDPVR (diastolic stiffness) 
robustly correlated with the extent of myocardial hypertrophy and fibrosis in ZDF rats. 
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Conclusions 
 
In the first project, we provided for the first time a detailed characterization and direct 
comparison of diabetic cardiomyopathy in T1DM and T2DM animal models. We have found 
that there are characteristic differences between the two types of DM in the development and 
properties of diabetic cardiomyopathy. Accordingly, different characteristics of myocardial 
dysfunction have been observed in T1DM and T2DM. T1DM was associated with overt 
systolic dysfunction indicated by the impairment of classical systolic parameters and 
sensitive, load-independent contractility indices. Moreover, active relaxation was deteriorated 
in type 1 diabetic animals. On the contrary, systolic function was preserved in diabetic 
cardiomyopathy in type 2 diabetic animals while severe diastolic dysfunction (impaired LV 
active relaxation, increased LV stiffness) developed. We have found an altered pattern of key 
pathophysiological features (nitro-oxidative stress, cardiac hypertrophy, fibrosis and 
cardiomyocyte apoptosis) in the diabetic heart. The NO-sGC-cGMP-PKG signaling pathway, 
have been shown to be severly deteriorated with the loss of its activity in the myocardium of 
both diabetic animal models. 
The second investigation focused on the effects of the sGC activator cinaciguat in T1DM-
associated diabetic cardiomyopathy. In this study, we have shown that pathological features 
of diabetic cardiomyopathy can be improved (nitro-oxidative stress, fibrosis, hypertrophy and 
apoptosis) by the application of cinaciguat, without affecting blood glucose levels. The anti-
oxidative, anti-fibrotic, anti-hypertrophic and anti-apoptotic effects might have been mediated 
via the reactivation of the NO-sGC-cGMP-PKG axis (indicated by increased plasma and 
cardiac cGMP levels and restored p-VASP/VASP ratio). Consequently, a significant 
improvement of cardiac function in T1DM could be observed.  
In the third study, effects of vardenafil treatment on the development of diabetic 
cardiomyopathy in T2DM have been investigated. Our study revealed the potential 
cardioprotective effects (anti-fibrotic, anti-oxidative, anti-apoptotic and anti-hypertrophic) of 
the PDE5A inhibitor vardenafil in T2DM-associated cardiomyopathy. We have shown that 
vardenafil, via the increase of plasma/cardiac cGMP and subsequent reactivation of the NO-
sGC-cGMP-PKG pathway (restored p-VASP/VASP ratio), is able improve T2DM-associated 
diabetic cardiomyopathy and it preserves physiological diastolic function in ZDF rats. 
Based on our results, the above modulators of the NO-sGC-cGMP-PKG pathway might 
become important therapeutic alternatives in the treatment of diabetic cardiomyopathy. 
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